Abemaciclib, aromatase inhibitor, Eli Lilly uye Kambani, endocrine kurapwa, Tamoxifen, Verzenio
Abemaciclib ine endocrine therapy inotenderwa neFDA muHER 2 yakanaka kenza yemazamu
Kurume 2023: Abemaciclib (Verzenio, Eli Lilly uye Kambani) uye endocrine therapy (tamoxifen kana aromatase inhibitor) zvakabvumidzwa neFood and Drug Administration (FDA) yekurapa adjuvant yevarwere vakuru vane ..
CAR T Cell therapy miedzo, Glioblastoma, glioblastoma miedzo, gliomas
Kuchengeteka uye Kubudirira Kudzidza kweAnti-B7-H3 CAR-T Cell Therapy yeRecurrent Glioblastoma
March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" design is used to determine Maximum..
American Society yeHematology, Carteyva, China, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Inopa Yazvino Clinical Dhata paCarteyva® muFollicular Lymphoma uye Mantle Cell Lymphoma paMusangano Wepagore wechi64 ASH.
SHANGHAI, CHINA, Zvita 12, 2022 Kambani yakazvimirira uye yekugadzira biotechnology inonzi JW Therapeutics (HKEX: 2126) inotarisa mukugadzira, kugadzira, uye kutengesa zvigadzirwa zvema cell immunotherapy. Pa64th American Society ..
dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly inotenderwa neFDA kune dMMR endometrial cancer
Kukadzi 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) yakapihwa mvumo yeFDA yekurapa varwere vakura vane kusawirirana kwekugadzirisa kushomeka (dMMR) inodzokororwa kana yepamberi endometrial cancer iyo yakawedzera panguva kana mushure mekare.
Daiichi Sankyo, DESTINY-Zamu04, Enhertu, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki inotenderwa neFDA kune HER2-yakaderera kenza yemazamu.
Nyamavhuvhu 2022: Kune varwere vakuru vane isingarambike kana metastatic HER2-yakaderera (IHC 1+ kana IHC 2+/ISH) kenza yemazamu avo vakambogamuchira chemotherapy munzvimbo yemetastatic kana vakasangana nechirwere kudzoka mukati kana mukati memakore matanhatu.
AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA
Olaparib inotenderwa kurapa adjuvant yegomarara rekutanga rezamu
Kurume 2022: Iyo Chikafu neDrug Administration yakabvumidza olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) yekurapa adjuvant yevarwere vakuru vane inobvisa kana fungidziro yekubvisa germline BRCA-mutated (gBRCAm) h.
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Mishonga inotenderwa kurapa gomarara rechiropa
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..
FDA, KRAS G12C, Lumakras, NSCLC, sotorasib
Iyo FDA yakabvumidza yekutanga kurapwa kwakanangwa kwekuchinja kwegomarara remapapu iyo yaimbofungidzirwa kuti isingarapike nemishonga.
Nyamavhuvhu 20, 2021: Munguva pfupi yapfuura muna Chivabvu, 2021 Lumakras (sotorasib) yakagamuchirwa neU.S.Food and Drug Administration semushonga wekutanga wevarwere vakuru vane gomarara risiri diki remapapu yemapapu avo vakamboita imwe chete yapfuura system ..
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, GADZIRA, USFDA
Pembrolizumab inogamuchirwa neDFA yekurapa kwekuwedzera kwe melanoma
Musi waKukadzi 15, 2019, pembrolizumab (KEYTRUDA, Merck) yakabvumidzwa neFood and Drug Administration yekurapa adjuvant yevarwere vane melanoma nekubatanidzwa kwemalymph node (s) mushure mekuvhiyiwa kwakazara. Kubvumirwa..
Ablynx, ADAMTS13, CABLIVI, chivote-yhdp, FDA, immunosuppressive kurapa, USFDA
Caplacizumab-yhdp inogamuchirwa neDFA
Musi waFebruary 6, 2019, pamwe chete nekutsinhana kweplasma uye kurapwa kwekuzvidzivirira muviri, Kudya neDrug Administration yakabvumidza caplacizumab-yhdp (CABLIVI, Ablynx NV) yevakuru varwere vane thrombotic cystopeni.